{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:09:11Z","timestamp":1789560551139,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ejogrb.2022.12.001","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T17:04:31Z","timestamp":1670259871000},"page":"29-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Primary prevention of cervical cancer in women: Human papillomavirus vaccine"],"prefix":"10.1016","volume":"281","author":[{"given":"Alice M.","family":"O'Neill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejogrb.2022.12.001_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ejogrb.2022.12.001_b0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0306-3356(21)00348-4","article-title":"7 - The Aetiology and Pathology of Cancer of the Cervix","volume":"3","author":"Anderson","year":"1976","journal-title":"Clin Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.ejogrb.2022.12.001_b0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/0002-9378(50)90422-4","article-title":"Contribution to the study of the etiology and prevention of cancer of the cervix of the uterus","volume":"60","author":"Gagnon","year":"1950","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ejogrb.2022.12.001_b0020","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0002-9378(15)30405-1","article-title":"Carcinoma of the cervix in nulliparous and celibate women","volume":"69","author":"Towne","year":"1955","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2022.12.001_b0025","unstructured":"The discoveries of human papilloma viruses that cause cervical cancer and of human immunodeficiency virus2008."},{"key":"10.1016\/j.ejogrb.2022.12.001_b0030","first-page":"569","article-title":"Human papilloma viruses and cancer","volume":"43","author":"zur Hausen","year":"1975","journal-title":"Bibl Haematol"},{"key":"10.1016\/j.ejogrb.2022.12.001_b0035","unstructured":"zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res. 1976;36(2 pt 2):794."},{"issue":"1","key":"10.1016\/j.ejogrb.2022.12.001_b0040","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/jvi.44.1.393-400.1982","article-title":"Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma","volume":"44","author":"Gissmann","year":"1982","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.ejogrb.2022.12.001_b0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ijc.2910290205","article-title":"Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNA","volume":"29","author":"Gissmann","year":"1982","journal-title":"Int J Cancer"},{"issue":"6006","key":"10.1016\/j.ejogrb.2022.12.001_b0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/314111a0","article-title":"Structure and transcription of human papillomavirus sequences in cervical carcinoma cells","volume":"314","author":"Schwarz","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.ejogrb.2022.12.001_b0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bpobgyn.2017.08.015","article-title":"The natural history of human papillomavirus infection","volume":"47","author":"de Sanjos\u00e9","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.ejogrb.2022.12.001_b0060","doi-asserted-by":"crossref","first-page":"e1002","DOI":"10.1002\/cti2.1002","article-title":"A vaccine to prevent cervical cancer: academic and industrial collaboration and a Lasker award","volume":"7","author":"Scolnick","year":"2018","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"10.1016\/j.ejogrb.2022.12.001_b0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","article-title":"Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.ejogrb.2022.12.001_b0070","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0042-6822(92)91251-O","article-title":"HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions","volume":"190","author":"Ghim","year":"1992","journal-title":"Virology"},{"issue":"24","key":"10.1016\/j.ejogrb.2022.12.001_b0075","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ejogrb.2022.12.001_b0080","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jmv.1890390414","article-title":"Evolution of the antibody response to human papillomavirus type 11 (HPV-11) in patients with condyloma acuminatum according to treatment response","volume":"39","author":"Bonnez","year":"1993","journal-title":"J Med Virol"},{"issue":"9528","key":"10.1016\/j.ejogrb.2022.12.001_b0085","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/S0140-6736(06)68921-6","article-title":"Finding a vaccine for human papillomavirus","volume":"367","author":"Frazer","year":"2006","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ejogrb.2022.12.001_b0090","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1073\/pnas.92.25.11553","article-title":"Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas","volume":"92","author":"Suzich","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.ejogrb.2022.12.001_b0095","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/jvi.69.6.3959-3963.1995","article-title":"Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.ejogrb.2022.12.001_b0100","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","article-title":"Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine","volume":"93","author":"Harro","year":"2001","journal-title":"JNCI: J Natl Cancer Institute"},{"issue":"21","key":"10.1016\/j.ejogrb.2022.12.001_b0105","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A Controlled Trial of a Human Papillomavirus Type 16 Vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2022.12.001_b0110","doi-asserted-by":"crossref","unstructured":"Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs. 2006;66(9):1263-71; discussion 72-3.","DOI":"10.2165\/00003495-200666090-00008"},{"key":"10.1016\/j.ejogrb.2022.12.001_b0115","unstructured":"Nancy B. Miller MD. Clinical Review of Biologics License Application for Human Papillomavirus 6, 11, 16, 18 L1 Virus Like Particle Vaccine (S. cerevisiae)."},{"key":"10.1016\/j.ejogrb.2022.12.001_b0120","unstructured":"(STN 125126 GARDASIL), manufactured by Merck, Inc. Food and Drug Administration. June 8, 2006."},{"issue":"5","key":"10.1016\/j.ejogrb.2022.12.001_b0125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejogrb.2022.12.001_b0130","doi-asserted-by":"crossref","unstructured":"Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. New Engl J Med 2007;356(19):1915-27.","DOI":"10.1056\/NEJMoa061741"},{"issue":"19","key":"10.1016\/j.ejogrb.2022.12.001_b0135","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2022.12.001_b0140","unstructured":"Gardasil European Medicines Agency2006 [updated 11\/01\/2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gardasil."},{"issue":"9783","key":"10.1016\/j.ejogrb.2022.12.001_b0145","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2022.12.001_b0150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.ejogrb.2022.12.001_b0155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003\u20132010","volume":"208","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.ejogrb.2022.12.001_b0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10286-019-00608-w","article-title":"Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society","volume":"30","author":"Barboi","year":"2020","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.ejogrb.2022.12.001_b0165","unstructured":"HSE. HPV Vaccine Safety and Effectiveness 2006 - 2022 2022 [updated 2 March 2022. Available from: https:\/\/www.hse.ie\/eng\/health\/immunisation\/hcpinfo\/othervaccines\/hpv\/hpvsafety\/."},{"issue":"14","key":"10.1016\/j.ejogrb.2022.12.001_b0170","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV Vaccination and the Risk of Invasive Cervical Cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejogrb.2022.12.001_b0175","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.amepre.2018.03.013","article-title":"Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction","volume":"55","author":"Guo","year":"2018","journal-title":"Am J Prev Med"},{"issue":"10","key":"10.1016\/j.ejogrb.2022.12.001_b0180","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/ijc.31231","article-title":"Vaccination protects against invasive HPV-associated cancers","volume":"142","author":"Luostarinen","year":"2018","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.ejogrb.2022.12.001_b0185","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"issue":"10197","key":"10.1016\/j.ejogrb.2022.12.001_b0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2022.12.001_b0195","unstructured":"HSE H. HSE School Vaccination Programme: HPV, Tdap, MenC\/MenACWY Uptake; 2021."},{"issue":"5","key":"10.1016\/j.ejogrb.2022.12.001_b0200","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"18","key":"10.1016\/j.ejogrb.2022.12.001_b0205","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.vaccine.2017.03.015","article-title":"Consensus statement from 17 relevant Japanese academic societies on the promotion of the human papillomavirus vaccine","volume":"35","author":"Iwata","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ejogrb.2022.12.001_b0210","unstructured":"(EMA) EMA. Pharmacovigilance Risk Assessment Committee (PRAC), Review concludes evidence does not support that HPV vaccines cause CRPS or POTS 2015 [Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Agenda\/2015\/11\/WC500196309.pdf."},{"key":"10.1016\/j.ejogrb.2022.12.001_b0220","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxj006","article-title":"Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease","volume":"28","author":"Dasbach","year":"2006","journal-title":"Epidemiol Rev"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211522006133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211522006133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:58:34Z","timestamp":1759557514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211522006133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":43,"alternative-id":["S0301211522006133"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2022.12.001","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary prevention of cervical cancer in women: Human papillomavirus vaccine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2022.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}